Development of Broad Coronavirus Immunity Targeting the Fusion Peptide

针对融合肽的广泛冠状病毒免疫的开发

基本信息

批准号：
10424573
负责人：
Daniel Kulp
金额：
$ 22.88万
依托单位：
WISTAR INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-06-09 至 2023-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10424573
关键词：
2019-nCoV Advanced Development Algorithm Design Animals Antibodies Antigens Award B-Lymphocytes Binding Biophysics COVID-19 COVID-19 pandemic COVID-19 patient Cellular Immunity China Cities Clinical Communicable Diseases Coronavirus Coronavirus spike protein DNA delivery Denmark Development Devices Disease Disease Outbreaks Electroporation Emergency Situation Epitopes Evaluation Frequencies Generations Genetic Human Humoral Immunities Immune Immune response Immunity Immunization Immunization Programs Investigation Length Link Middle East Respiratory Syndrome Middle East Respiratory Syndrome Coronavirus Mink Mutate Mutation Parents Peptides Pharmaceutical Preparations Plasmids Polymerase Polysaccharides Population Proteins Publishing Reagent Recovery SARS coronavirus SARS-CoV-2 spike protein Site Structure Technology Therapeutic Time Translations United States National Institutes of Health Vaccine Clinical Trial Vaccines Virus Widespread Disease Zoonoses animal data base combat convalescent plasma coronavirus vaccine cross reactivity design experimental study human coronavirus immunogenic improved inhibitor interest medical countermeasure nanoparticle neutralizing antibody novel coronavirus nucleic acid delivery plasmid DNA pre-clinical remdesivir response small molecule transmission process vaccine effectiveness

项目摘要

Project Summary This revised application was originally responding to the Emergency Award ‘Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)’ submitted through PAR-20-177. However, we are submitting the revised application, upon advice from NIH, to the parent PA-20-195 with a due date of Nov 16th 2020. The application is titled ‘Development of Broad Coronavirus Immunity Targeting the Fusion Peptide’. The assembled team brings together highly complementary expertise in order to develop a unique coronavirus vaccine approach to provide more effective, focused and broadened humoral immunity. This proposal focuses on the fusion peptide site of vulnerability as it has been understudied, it is highly conserved and recently been identified as an epitope of neutralizing antibodies in human convalescent sera. The project aims are: (1) Develop pan- coronavirus fusion peptide nanoparticle and trimer immunogens (2) Develop immunization regimes to induce broadly neutralizing antibodies using nucleic acid delivery.

项目概要此修订后的申请最初是响应紧急奖“快速调查严重事件” 急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 和 2019 年冠状病毒病 (COVID-19)’ 通过 PAR-20-177 提交，但是，我们根据 NIH 的建议将修改后的申请提交给母版 PA-20-195，截止日期为 2020 年 11 月 16 日。该申请的标题为“Development of Broad” 针对融合肽的冠状病毒免疫”。聚集的团队高度团结。互补的专业知识，以开发独特的冠状病毒疫苗方法，提供更有效、该提案重点关注并扩大了体液免疫的融合肽位点。脆弱性，因为它已被充分研究，它是高度保守的，最近被确定为人类恢复期血清中和抗体的表位该项目的目标是：（1）开发泛- 冠状病毒融合肽纳米颗粒和三聚体免疫原（2）开发免疫方案以诱导使用核酸递送广泛中和抗体。